Nuvo Pharmaceuticals Inc
TSX:MRV
Nuvo Pharmaceuticals Inc
TSX:MRV
Price:
1.35 CAD
Market Closed
Updated:
May 5, 2024
Nuvo Pharmaceuticals Inc
Operating Income
|
Nuvo Pharmaceuticals Inc
Operating Income Peer Comparison
Comparables:
BHC
WEED
CRON
C
CURA
T
TER
Competitive Operating Income Analysis
Latest Figures & CAGR of Competitors
Latest Figures & CAGR of Competitors
| Company | Operating Income | CAGR 3Y | CAGR 5Y | CAGR 10Y | |
|---|---|---|---|---|---|
|
|
Nuvo Pharmaceuticals Inc
TSX:MRV
|
Operating Income
CA$12.4m
|
CAGR 3-Years
N/A
|
CAGR 5-Years
29%
|
CAGR 10-Years
N/A
|
|
|
Bausch Health Companies Inc
TSX:BHC
|
Operating Income
$1.6B
|
CAGR 3-Years
7%
|
CAGR 5-Years
26%
|
CAGR 10-Years
6%
|
|
|
Canopy Growth Corp
TSX:WEED
|
Operating Income
-CA$337.4m
|
CAGR 3-Years
25%
|
CAGR 5-Years
5%
|
CAGR 10-Years
N/A
|
|
|
Cronos Group Inc
TSX:CRON
|
Operating Income
-$79.9m
|
CAGR 3-Years
22%
|
CAGR 5-Years
-30%
|
CAGR 10-Years
N/A
|
|
C
|
Curaleaf Holdings Inc
CNSX:CURA
|
Operating Income
$12.2m
|
CAGR 3-Years
N/A
|
CAGR 5-Years
N/A
|
CAGR 10-Years
N/A
|
|
T
|
Terrascend Corp
CNSX:TER
|
Operating Income
-$23.7m
|
CAGR 3-Years
N/A
|
CAGR 5-Years
N/A
|
CAGR 10-Years
N/A
|
See Also
What is Nuvo Pharmaceuticals Inc's Operating Income?
Operating Income
12.4m
CAD
12.4m
CAD
Based on the financial report for Sep 30, 2022, Nuvo Pharmaceuticals Inc's Operating Income amounts to 12.4m CAD.
What is Nuvo Pharmaceuticals Inc's Operating Income growth rate?
Operating Income CAGR 5Y
29%
29%
Over the last year, the Operating Income growth was -19%.
You don't have any saved screeners yet
